Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 107,464 | 64,381 | 57,424 | 51,346 | 55,311 |
| Gross Profit | 107,464 | 64,381 | 57,424 | 51,346 | 55,311 |
| Operating Expenses | 111,066 | 111,330 | 113,459 | 143,303 | 313,095 |
| Operating Income | -3,602 | -46,949 | -56,035 | -91,957 | -257,784 |
| Interest Expense | 2,461 | 2,546 | 2,350 | 6,369 | 8,547 |
| Other Income | 135,310 | 4,881 | 9,116 | 5,511 | 1,109 |
| Pre-tax Income | 129,247 | -44,614 | -49,269 | -92,815 | -265,222 |
| Income Tax | 23,352 | 11,804 | 5,924 | 9 | -151 |
| Net Income Continuous | 105,895 | -56,418 | -55,193 | -92,824 | -265,071 |
| Net Income Discontinuous | N/A | N/A | N/A | 964,956 | 65,645 |
| Net Income | $105,895 | $-56,418 | $-55,193 | $872,132 | $-199,426 |
| EPS Basic Total Ops | 2.10 | -1.15 | -1.00 | 11.85 | -2.87 |
| EPS Basic Continuous Ops | 2.10 | -1.16 | -1.00 | -1.26 | -3.82 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | 13.11 | 0.95 |
| EPS Diluted Total Ops | 2.06 | -1.15 | -1.00 | 11.85 | -2.87 |
| EPS Diluted Continuous Ops | 2.06 | -1.16 | -1.00 | -1.26 | -3.82 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | 13.11 | 0.95 |
| EPS Diluted Before Non-Recurring Items | -0.50 | -1.15 | -1.00 | -1.26 | -2.87 |
| EBITDA(a) | $-4,806 | $-47,748 | $-55,931 | $-88,922 | $-252,972 |